

Jody L Green

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8031730/publications.pdf>

Version: 2024-02-01

40
papers

2,017
citations

687220

13
h-index

289141

40
g-index

41
all docs

41
docs citations

41
times ranked

1688
citing authors

#	ARTICLE	IF	CITATIONS
1	Adverse Events Related to Accidental Unintentional Ingestions From Cough and Cold Medications in Children. <i>Pediatric Emergency Care</i> , 2022, 38, e100-e104.	0.5	2
2	Characterizing the Experience of Tapentadol Nonmedical Use: Mixed Methods Study. <i>JMIR Formative Research</i> , 2022, 6, e16996.	0.7	2
3	Prescription Stimulant Nonmedical Use Among Adolescents Evaluated for Substance Use Disorder Treatment (CHAT _{a,c}). <i>Journal of Attention Disorders</i> , 2021, 25, 1859-1870.	1.5	8
4	Real-World Data on Nonmedical Use of Tramadol from Patients Evaluated for Substance Abuse Treatment in the NAVIPPRO Addiction Severity Index [®] Multimedia Version (ASI-MV [®]) Network. <i>Drug Safety</i> , 2021, 44, 235-244.	1.4	6
5	Impact of product safety changes on accidental exposures to liquid laundry packets in children. <i>Clinical Toxicology</i> , 2021, 59, 392-399.	0.8	1
6	Trends in adverse events and related health-care facility utilization from cough and cold medication exposures in children. <i>Clinical Toxicology</i> , 2021, 59, 351-354.	0.8	3
7	Characterizing prescription stimulant nonmedical use (NMU) among adults recruited from Reddit. <i>Addictive Behaviors Reports</i> , 2021, 14, 100376.	1.0	6
8	Pediatric Fatalities Associated With Over-the-Counter Cough and Cold Medications. <i>Pediatrics</i> , 2021, 148, .	1.0	11
9	Adverse events associated with diphenhydramine in children, 2008 [–] 2015. <i>Clinical Toxicology</i> , 2020, 58, 99-106.	0.8	13
10	Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation Strategy. <i>Pain Medicine</i> , 2020, 21, 92-100.	0.9	4
11	Medication Errors From Over-the-Counter Cough and Cold Medications in Children. <i>Academic Pediatrics</i> , 2020, 20, 327-332.	1.0	10
12	Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index [®] Multimedia Version (ASI-MV). <i>Pain Medicine</i> , 2020, 21, 1891-1901.	0.9	10
13	The impact of the prescription opioid epidemic on young children: Trends and mortality. <i>Drug and Alcohol Dependence</i> , 2020, 211, 107924.	1.6	8
14	How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e16038.	1.2	5
15	Flow Restrictors and Reduction of Accidental Ingestions of Over-the-Counter Medications. <i>American Journal of Preventive Medicine</i> , 2019, 56, e205-e213.	1.6	6
16	Understanding multi [–] pill ingestion of prescription opioids: Prevalence, characteristics, and motivation. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 117-121.	0.9	6
17	Medication Errors With Pediatric Liquid Acetaminophen After Standardization of Concentration and Packaging Improvements. <i>Academic Pediatrics</i> , 2018, 18, 563-568.	1.0	11
18	Adverse events associated with opioid-containing cough and cold medications in children. <i>Clinical Toxicology</i> , 2018, 56, 1162-1164.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Frequency of Poison Center Exposures for Pediatric Accidental Unsupervised Ingestions of Acetaminophen after the Introduction of Flow Restrictors. <i>Journal of Pediatrics</i> , 2018, 198, 254-259.e1.	0.9	15
20	Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System. <i>Journal of Pain</i> , 2018, 19, 439-453.	0.7	39
21	Unit-Dose Packaging and Unintentional Buprenorphine-Naloxone Exposures. <i>Pediatrics</i> , 2018, 141, e20174232.	1.0	14
22	Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV [®] substance use disorder treatment centers and RADARS [®] System Poison Centers. <i>Journal of Substance Abuse Treatment</i> , 2018, 84, 42-49.	1.5	13
23	Evaluation of the quality and value of data sources for postmarket surveillance of the safety of cough and cold medications in children. <i>BMC Medical Research Methodology</i> , 2018, 18, 175.	1.4	7
24	Consistency Between Opioid-Related Mortality Trends Derived From Poison Center and National Vital Statistics System, United States, 2006–2016. <i>American Journal of Public Health</i> , 2018, 108, 1639-1645.	1.5	22
25	UK survey of non-medical use of prescription drugs (NMURx) as a valuable source of general population illicit drug use data. <i>Postgraduate Medical Journal</i> , 2018, 94, 627-633.	0.9	8
26	Safety Profile of Cough and Cold Medication Use in Pediatrics. <i>Pediatrics</i> , 2017, 139, .	1.0	30
27	Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. <i>Drug and Alcohol Dependence</i> , 2017, 175, 140-145.	1.6	39
28	Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1061-1070.	0.9	8
29	Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1044-1052.	0.9	12
30	Adverse events associated with pediatric exposures to dextromethorphan. <i>Clinical Toxicology</i> , 2017, 55, 25-32.	0.8	14
31	The prescription paradox of acetaminophen safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 599-601.	0.9	6
32	Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System. <i>Journal of Pain</i> , 2016, 17, 745-752.	0.7	14
33	Trends in abuse and misuse of prescription opioids among older adults. <i>Drug and Alcohol Dependence</i> , 2015, 149, 117-121.	1.6	144
34	Abuse-Deterrent Formulations of Prescription Opioids. <i>JAMA Psychiatry</i> , 2015, 72, 849.	6.0	1
35	Abuse and diversion of buprenorphine sublingual tablets and film. <i>Journal of Substance Abuse Treatment</i> , 2014, 47, 27-34.	1.5	84
36	Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis. <i>Western Journal of Emergency Medicine</i> , 2013, 14, 218-226.	0.6	91

#	ARTICLE	IF	CITATIONS
37	2010 Annual Report of the American Association of Poison Control Centers™ National Poison Data System (NPDS): 28th Annual Report. Clinical Toxicology, 2011, 49, 910-941.	0.8	342
38	2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clinical Toxicology, 2010, 48, 979-1178.	0.8	310
39	2008 Annual Report of the American Association of Poison Control Centers™ National Poison Data System (NPDS): 26th Annual Report. Clinical Toxicology, 2009, 47, 911-1084.	0.8	327
40	2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report. Clinical Toxicology, 2008, 46, 927-1057.	0.8	362